Alixorexton
InvestigationalAlso known as: ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Research Statistics
Orexin-2 agonist with solid Phase 2 human data; well-characterized receptor mechanism.
Research Dossier
Overview
What is Alixorexton and what does the research say?
Mechanism of Action
Alixorexton is an orexin receptor 2 (OX2R) selective agonist that directly addresses the pathophysiology of narcolepsy type 1 by restoring orexin signaling lost due to autoimmune destruction of orexin-producing neurons.
How It Works (Simplified)
Alixorexton acts as a replacement signal for the missing orexin in narcolepsy patients:
Selectively binds and activates orexin receptor 2 in wake-promoting brain regions, mimicking the natural orexin signal that is absent in NT1 patients.
Triggers Gq-protein signaling cascade leading to neuronal depolarization and increased firing in the tuberomammillary nucleus, locus coeruleus, and other arousal centers.
Promotes release of histamine, norepinephrine, dopamine, and acetylcholine from wake-promoting neurons, collectively maintaining the wakeful state.
Restores orexin-mediated inhibition of inappropriate muscle atonia during wakefulness, reducing sudden loss of muscle tone triggered by emotions.
Scientific Pathways
OX2R-Gq Signaling Pathway (Wakefulness Promotion)
Alixorexton → OX2R binding → Gq/11 activation → PLC → IP3/DAG
↓
Calcium release + PKC activation
↓
Neuronal depolarizationWake-Promoting Neurotransmitter Cascade (Arousal Network)
OX2R activation in hypothalamus → TMN (histamine) + LC (norepinephrine) + VTA (dopamine)
↓
Sustained cortical activation and wakefulnessKey Research: Willie JT et al. (2003) demonstrated that OX2R knockout mice exhibit severe narcolepsy phenotype, validating OX2R as the critical target for wakefulness. PMID:14622577
Important Limitations
- Phase 3 clinical trial data not yet available
- Long-term efficacy and safety with chronic use unknown
- Optimal dosing for different patient populations not established
- No head-to-head trials against current standard of care (sodium oxybate, stimulants)
- Investigational drug not approved by FDA or any regulatory agency
- Unknown whether efficacy extends to narcolepsy type 2 (without orexin deficiency)
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on Phase 2 data: Initial improvements in daytime wakefulness may be observed. Oral bioavailability and CNS penetration allow for rapid onset of OX2R occupancy. Some patients report subjective improvement in alertness within first week.
Continued improvement in MWT scores observed in clinical trials. Reduction in cataplexy frequency becomes more apparent. Patients typically report improved ability to maintain wakefulness during daily activities.
Near-maximal efficacy observed in Phase 2 studies. ESS scores significantly improved. Sleep architecture improvements may become more pronounced with consolidated nighttime sleep and daytime wakefulness.
Long-term efficacy and durability being evaluated in extension studies. Phase 3 trials will establish sustained benefit profile. Unknown if tolerance develops with chronic OX2R agonism.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Alixorexton product quality
Good Signs (5 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Alixorexton with other peptides. Based on published research and mechanistic considerations.
Modafinil
CompatibleDifferent mechanisms of action. Modafinil works via dopamine reuptake inhibition while alixorexton directly activates OX2R. Potential additive wake-promoting effects, though clinical combination data is lacking.
Sodium-Oxybate
CompatibleComplementary mechanisms. Sodium oxybate acts on GABA-B receptors primarily during sleep, while alixorexton promotes daytime wakefulness via OX2R. May allow dose reduction of either agent.
Oveporexton
CautionBoth are orexin receptor agonists. Oveporexton is a dual OX1R/OX2R agonist while alixorexton is OX2R-selective. Concurrent use would cause overlapping receptor activation. No clinical rationale for combination.
Danavorexton
CautionBoth target OX2R. Danavorexton is an IV formulation while alixorexton is oral. Combined use would result in excessive OX2R stimulation without additional benefit.
Suvorexant
AvoidSuvorexant is an orexin receptor antagonist, directly opposing alixorexton's mechanism. Concurrent use would result in pharmacological antagonism, negating therapeutic effects of both drugs.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Alixorexton
Related Peptides
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank, N-Acetyl Selank, Acetyl-Selank-Amidate +1 more
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.